| REVIEW ARTICLE |
|
| Year : 2017 | Volume
: 21
| Issue : 6 | Page : 898-902 |
|
|
Gemigliptin: Newer promising gliptin for type 2 diabetes mellitus
Manish Gutch1, Abhay Joshi2, Sukriti Kumar3, Avinash Agarwal1, Rajendra Kumar Pahan4, Syed Mohd Razi5
1 Department of Medicine, King George's Medical College, Lucknow, Uttar Pradesh, India
2 Regional Medical Advisor, Sanofi India Ltd, Mumbai, Maharashtra, India
3 Department of Radiodiagnosis, King George's Medical College, Lucknow, India
4 Department of Cardiology, RML Hospital, Lucknow, India
5 Department of Endocrinology, LLRM Medical College, Meerut, Uttar Pradesh, India
Correspondence Address:
Manish Gutch
Department of Medicine, King George's Medical College, Lucknow, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijem.IJEM_20_17
|
|
|
The dipeptidyl peptidase-4 (DPP-4) inhibitors have facilitated the management of type 2 diabetes mellitus (T2DM) owing to their superior efficacy and safety with low incidence of adverse effects. Gemigliptin is a new member of this family of drugs, and studies have revealed certain advantages of gemigliptin use compared to its previous congeners. Besides, this drug has also been studied for the treatment of T2DM as monotherapy, in combination with metformin or other oral antidiabetic drugs and in T2DM with moderate-to-severe renal failure. In this review, we explore the published data highlighting the pharmacology, efficacy, and safety of gemigliptin along with its recommendations for use in patients with T2DM. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
